Drug intelligence / Profile preview

bisoprolol (TOA EIYO)

Development stage: Unknown
Lead developer: TOA Eiyo
Modality: Small Molecules
Administration: Transdermal

Overview

TY-0201R is a transdermal patch formulation of bisoprolol, a selective beta-1 adrenergic receptor blocker, developed by TOA Eiyo for the treatment of essential hypertension. The patch contains bisoprolol in its free base form and is designed for once-daily application, providing a non-invasive delivery route that ensures stable plasma concentrations and avoids the first-pass metabolism associated with oral administration. TY-0201R is specifically the designation for the formulation evaluated in clinical trials in China, including a Phase III study comparing its efficacy and safety to oral bisoprolol fumarate in patients with Grade 1 or 2 essential hypertension.

Other names: bisoprolol transdermal patch

Targets

ADRB1 (β1)

Beyond the preview

Go deeper on bisoprolol (TOA EIYO).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bisoprolol (TOA EIYO).

Explore the full profile